Investment Landscape: Corticobasal Degeneration covers the current R&D investment,
clinical trial pipeline, and funding trends for Corticobasal Degeneration research.
Last updated: 2026-04-01 09:38 PT
Total Clinical Trials: 0
Active Trials (Recruiting/Active): 0
Corticobasal Degeneration has 0 total clinical trials, representing a rare and heterogeneous neurodegenerative condition. The tau pathology overlap with PSP creates opportunities for cross-disease therapeutic development.
CBD research is benefiting from improved diagnostic criteria and tau PET imaging. The heterogeneity of CBD presentations is driving personalized therapeutic approaches. Anti-tau therapies developed for PSP may have applications in CBD given shared pathology.
Only 0.0% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Last updated: 2026-04-01